Preparation and in Vitro Characterizations of Cyclosporine A Ocular Nanostructured Lipid Carriers

Chinese Pharmaceutical Journal ›› 2012, Vol. 47 ›› Issue (5) : 362-366.

PDF(1193 KB)
PDF(1193 KB)
Chinese Pharmaceutical Journal ›› 2012, Vol. 47 ›› Issue (5) : 362-366.

Preparation and in Vitro Characterizations of Cyclosporine A Ocular Nanostructured Lipid Carriers

Author information +
History +

Abstract

OBJECTIVE To develop an appropriate nanostructured lipid carrier (CsA-NLC) for ocular drug delivery of cyclosporine A and its in vitro physicochemical properties and ocular irritation studies were investigated. METHODS The melt-emulsification method was chosen to prepare CsA-NLC. The formulation was optimized by orthogonal design. The morphology of CsA-NLC was observed by transmission electron microscopy (TEM). The mean particle size and Zeta potential were measured by laser particle size analyzer. The state of drug in NLC was confirmed by DSC. Drug loading and encapsulation efficiency were determined by HPLC. Dialysis method at 34 ℃ was employed to investigate the in vitro release of CsA-NLC. The topical ocular irritation study of CsA-NLC was made in rabbits. RESULTS The obtained CsA- NLC was approximately spherical in shape with average particle size of (35.9±0.21) nm and zeta potential of (-13.9±0.21) mV. The drug loading and encapsulation efficiency were (16.2±0.09)% and (97.5±0.58)%， respectively. The in vitro release of CsA- NLC was slowed down and fitted well single exponential distribution model. There was no irritation for CsA-NLC to rabbits eye. CONCLUSION CsA- NLC with small particle sizes and high drug loading， slow release would be a promising nanocarrier for ocular drug delivery to improve drugs bioavailability.

Key words

cyclosporine A / nanostructured lipid carriers / ocular drug delivery / preparation / physicochemical properties / ocular irritation

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
Preparation and in Vitro Characterizations of Cyclosporine A Ocular Nanostructured Lipid Carriers[J]. Chinese Pharmaceutical Journal, 2012, 47(5): 362-366

References


[1] OH C， APEL A， SAVILLE B， et al. Local efficacy of cyclosporine in corneal transplant therapy [J]. Curr Eye Res， 1994， 13(5)： 337-343.
[2] MURPHY C， GREINER K， PLSKOVA J， et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis [J]. Arch Ophthalmol， 2005， 123(5)： 634-641.
[3] ENYEDI L， PEARSON P， ASHTON P， et al. An intravitreal device providing sustained release of cyclosporine and dexamethasone [J]. Curr Eye Res， 1996， 15(5)： 549-557.
[4] TANG D， ACHEAMPONG A. Ocular pharmacokinetics and safety of ciclosporin， a novel topical treatment for dry eye [J]. Clin Pharmacokinet， 2005， 44(3)： 247-261.
[5] JIANG W J， XU Q W. Preparation and preliminary stability evaluation of cyclosporine A ocular microemulsion [J]. Chin J Pharm(中国医药工业杂志)， 2007， 38(5)： 351-353.
[6] KUWANO M， IBUKI H， MORIKAWA N， et al. Cyclosporine A formulation affects its ocular distribution in rabbits [J]. Pharm Res， 2002， 19(1)： 108-111.
[7] SUN K X， QI Y H， WU R J， et al. Ocular absorption and distribution of liposomal ciclosporin in rabbits [J]. Chin J Clin Pharm (中国临床药学杂志)， 2004， 13(1)：22-25.
[8] CALVO P， SANCHEZ A， MARTINEZ J， et al. Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A [J]. Pharm Res， 1996， 13(2)： 311-315.
[9] ENRIQUEZ D， SALAMANCA A， DIEBOLD Y， et al. Chitosan nanoparticles as a potential drug delivery system for the ocular surface： toxicity， uptake mechanism and in vivo tolerance [J]. Invest Ophthalmol Vis Sci， 2006， 47(4)： 1416-1425.
[10] LI X， NIE S F， KONG J， et al. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers [J]. Int J Pharm， 2008， 363(1-2)： 177-182.
[11] CALVO P， THOMAS C， ALONSO M. Study of the mechanism of interaction of poly (ε-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy [J]. Int J Pharm， 1994， 103(3)： 283-291.
[12] LIN H R， SUNG K C. Carbopol/pluronic phase change solutions for ophthalmic drug delivery [J]. J Controlled Release， 2000， 69 (3)： 379-388.
[13] JANNIN V， POCHARD E， CHAMBIN O. Influence of poloxamers on the dissolution performance and stability of controlled-release formulations containing precirol ATO 5 [J]. Int J Pharm， 2006， 309(1-2)： 6-15.
PDF(1193 KB)

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉